期刊
SEMINARS IN ONCOLOGY
卷 41, 期 5, 页码 685-699出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminoncol.2014.08.007
关键词
-
类别
资金
- PHS [RO1CA138188, RO1CA110249, R21 CA164756, R21CA173120, R03CA175957]
- National Cancer Institute
- Fondazione Umberto Veronesi Post Doctoral Fellowship
- Fondazione Umberto Veronesi
- Susan Komen Post Doctoral Fellowship [KG111486]
- Susan G. Komen for the Cure Foundation
A growing body of experimental and clinical evidence strongly suggests that the resistance of cancer-initiating cells (CICs) to conventional therapies represents a major obstacle to the successful treatment of a malignant disease. To overcome this limitation a novel combinatorial tumor antigen (TA)-specific monoclonal antibody (mAb) strategy has been developed. In this strategy TA-specific mAbs are combined with chemotherapeutic agents and/or small molecules that inhibit aberrantly activated signaling pathways in cancer cells and especially in CICs. The in vitro results we have obtained indicate that this strategy is very effective in eradicating both differentiated cancer cells and CICs in several types of malignant disease. If the in vitro results have in vivo relevance, the strategy we have designed may have an impact on the treatment of malignant diseases. (C) 2014 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据